Prelude Therapeutics Inc 8-K

What Happened

• Prelude Therapeutics Incorporated (PRLD) issued a press release on March 10, 2026 announcing its financial results for the year ended December 31, 2025. The press release is attached to the company's Form 8-K as Exhibit 99.1.
• The company also furnished an investor presentation to be used by management in investor presentations; that presentation is attached as Exhibit 99.2. The Form 8-K was signed by Bryant Lim, Chief Financial Officer and Chief Legal Officer, on March 10, 2026.

Key Details

• Item reported: 2.02 (Results of Operations and Financial Condition) — press release disclosing 2025 financial results.
• Item reported: 7.01 (Regulation FD Disclosure) — investor presentation materials furnished for use in management presentations.
• Both the press release and presentation are being furnished (Exhibits 99.1 and 99.2) and are expressly stated as not “filed” under Section 18 of the Exchange Act and not incorporated by reference into other filings.
• Form 8-K filing date: March 10, 2026; fiscal year covered by results: year ended December 31, 2025.

Why It Matters

• This 8-K gives investors the company’s reported full-year 2025 financial results and the current investor presentation — primary sources for earnings, revenue, cash position, and management commentary.
• Because the materials are furnished (not filed), they are timely disclosures of results and investor materials but are subject to different legal treatment than filed disclosure. Investors should review the attached press release and presentation for specific figures and context.